TrialNet follow-on studies
The TrialNet Pathway to Prevention study screens for autoantibodies to four different components of the insulin-producing beta cells in the islets of the pancreas:
-
Insulin
-
Glutamic acid decarboxylase
-
Islet antigen-2
-
Zinc transporter 8
It also measures how well the body can control glucose levels after a glucose drink (the oral glucose test) to assess risk of disease. The results of these tests determine which of the following studies are offered to high-risk individuals:
-
Abatacept
-
LIFT
CTLA4-Ig (Abatacept) for Prevention of Type 1 Diabetes in Relatives At-Risk
This study is for:
-
TrialNet Pathway to Prevention Study participants who have two or more antibodies other than insulin autoantibody
About this study
Abatacept is used to treat rheumatoid arthritis and other autoimmune diseases. In 2011, the TrialNet consortium showed that it preserved pancreas function in people with recently-diagnosed T1D (link to Lancet 2011; 378: 412–19). We are now testing whether Abatacept also preserves pancreas function earlier in the course of T1D.
This is a randomised controlled trial, meaning one half of the participants are randomly allocated to receive Abatacept and the other half to placebo (dummy treatment). Participation involves 13 monthly infusions at a research unit followed by 6-monthly follow-up visits.
This trial is running in Adelaide and Melbourne.
For more information about this study
Long-Term Investigative Follow-Up in TrialNet (LIFT) Study
This study is for:
-
People who have joined the Pathway to Prevention Study and subsequently developed T1D
About this study
LIFT aims to identify factors associated with preservation of pancreas function early in the course of T1D. This will improve our ability to develop treatments that protect the pancreas and improve glucose control in the first few years after diabetes is diagnosed.
Participation involves 6-monthly visits for oral glucose tests and blood sampling.
For more information about this study
